Summary

DSIP is a nine-amino-acid neuropeptide first isolated from rabbit brain in the 1970s that has been investigated for its ability to promote slow-wave sleep, modulate stress responses, and normalise physiological functions. Clinical evidence remains limited and inconclusive, though the compound has a long research history.

Mechanism

The precise mechanism of DSIP is not fully elucidated. It is thought to act on GABAergic and serotonergic systems, modulating slow-wave sleep induction. DSIP may influence the HPA axis by modulating CRF and ACTH release. It has been detected in multiple tissues including the brain, gut, and peripheral organs, suggesting pleiotropic effects. Unlike benzodiazepines or Z-drugs, DSIP does not appear to act on GABA-A receptors directly but may modulate endogenous sleep-promoting pathways.

Evidence base

Evidence Grading: Limited

Human clinical data: Small studies (n<50) from the 1980s–1990s show inconsistent sleep-promoting effects. No modern large-scale RCTs exist.

Animal data: More robust evidence for sleep-inducing and stress-modulating effects in rodents and rabbits.

Key limitations: Most studies are decades old, from small laboratories, with methodological limitations. No replication in modern settings. Mechanism remains poorly understood.

Verdict: DSIP remains an intriguing research compound but lacks sufficient modern clinical evidence to support therapeutic claims.

Protocols

Published research and discussion contexts reference doses of 100–300 mcg administered subcutaneously, typically before sleep. Intranasal administration has also been explored. Cycles of 2–4 weeks with breaks are commonly discussed. No modern pharmacokinetic data exists to confirm optimal dosing.

DSIP is not a licensed medicine in the UK and is not a controlled substance under the Misuse of Drugs Act. It occupies a UK grey area when sold as a research chemical. MHRA guidance on research peptides (2026) tightened labelling requirements; products marketed for human consumption would constitute unlicensed medicine offences.

Vendor notes

DSIP is available from some UK-based research peptide suppliers. Purity and quality can vary significantly; verify COAs. See the vendor vetting guide for evaluation criteria.

References

  1. Schoenenberger GA, et al. Characterization of a delta-electroencephalogram (-sleep)-inducing peptide. Proceedings of the National Academy of Sciences. 1977;74(3):1282-1286.
  2. Schneider-Helmert D. Clinical evaluation of DSIP. In: Inoué S, Schneider-Helmert D (eds). Sleep Peptides: Basic and Clinical Approaches. Springer; 1984:239-254.
  3. Graf MV, Kastin AJ. Delta-sleep-inducing peptide (DSIP): a review. Neuroscience & Biobehavioral Reviews. 1986;10(2):215-245.
  4. Mikhaleva II, et al. Delta sleep-inducing peptide (DSIP): structure, functions, and prospects. Russian Journal of Bioorganic Chemistry. 2019;45(5):269-278.